Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Seekyo Therapeutics logo — Tumor Activated Therapy: targeting Tumor Micro-Environment...

Seekyo Therapeutics

Tumor Activated Therapy: targeting Tumor Micro-Environment functional proteins to induce tumor self-destruction

Founded 2018 France France 6 employees Seed Total: $1.45M Biotechnology, Health and Wellness +1

General Information

Company Name Seekyo Therapeutics
Founded Year 2018
Location France France
Employees 6
Industries Biotechnology, Health and Wellness, Life Sciences
Funding Stage Seed
Social

BounceWatch is an independent company data service, not affiliated with Seekyo Therapeutics. To contact Seekyo Therapeutics, visit seekyo-therapeutics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About Seekyo Therapeutics

Seekyo Therapeutics is a pre-clinical biotech company founded in 2018. Based in France, the company focuses on the development of tumor-activated therapies for the treatment of solid cancers, such as pancreas and Triple Negative Breast Cancer (TNBC). Seeking to overcome the heterogeneity of cancer cells, Seekyo targets specific functional proteins within the Tumor Micro-Environment (TME) to induce tumor self-destruction. The company's lead compound, SKY01, has demonstrated promising results, including efficacy and safety validation in small and large animals, unprecedented antitumor efficacy compared to standard treatments, and effectiveness across various tumor types, including pancreas, TNBC, lung, and colorectal cancers. Additionally, the treatment boasts a relatively low cost of goods, enhancing its potential economic viability. In March 2021, Seekyo Therapeutics secured a €650.00K seed round investment from Bpifrance, signaling investor confidence in the company's innovative approach to cancer treatment. As the company continues to advance its pre-clinical developments, the latest investment positions Seekyo for further progress in its mission to revolutionize cancer therapy through targeted interventions within the Tumor Micro-Environment.

Taxonomy: Biotech Innovations, Oncology Therapeutics, Cancer Treatment, Drug Delivery Systems, Tumor Microenvironment, Anticancer Agents, Chemotherapy Advancements, Smart Molecular Systems, Life Science Innovations, Therapeutic Vectors, Solid Tumor Therapy, Enzyme-Responsive Technology, Preclinical Biotech, Tumor Self-Destruction, Targeted Cancer Therapies

Services & Products

Development of Tumor Micro-Environment targeted therapies

Target Customers

Patients with solid cancers Biotech companies Big Pharma Academics

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round €650.00K 1
Bpifrance
Bpifrance
18 Mar 2021
Seed Round €650.00K 1
French Tech Acceleration Fund
20 Jan 2020
Debt Financing €150.00K 1
EIF
EIF
20 Jan 2020

Seekyo Therapeutics Alternatives & Competitors

View All Alternatives
Seekyo Therapeutics vs
VitroScan
VitroScan The Netherlands

Predictive Testing Solutions

Grant
10 employees
Biopharma, Biotechnology
Seekyo Therapeutics vs
Oniria Therapeutics
Oniria Therapeutics Spain

A shift in cancer treatment methodology makes a world of difference.

Seed
16 employees
Biopharma, Biotechnology
Seekyo Therapeutics vs
ImmunoBiochem Corporation
ImmunoBiochem Corporation Canada

Improving patient outcomes through innovations in biological therapeutics

Seed
4 employees
Biotechnology, Health Care
View all alternatives

FAQ About Seekyo Therapeutics

Tumor Activated Therapy: targeting Tumor Micro-Environment functional proteins to induce tumor self-destruction
Seekyo Therapeutics was founded in 2018.
Seekyo Therapeutics is headquartered in France.
Seekyo Therapeutics operates in Biotechnology, Health and Wellness and Life Sciences. Its work centres on Biotech Innovations, Oncology Therapeutics, Cancer Treatment and Drug Delivery Systems. Its customers include Patients with solid cancers, Biotech companies and Big Pharma.
Seekyo Therapeutics has approximately 6 employees.
Seekyo Therapeutics has completed 3 funding rounds, raising a total of $1.45M. The latest funding stage is Seed.
Seekyo Therapeutics offers: Development of Tumor Micro-Environment targeted therapies.
Top alternatives and competitors to Seekyo Therapeutics include VitroScan, Oniria Therapeutics, ImmunoBiochem Corporation, TransCode Therapeutics, Inc., Myricx Bio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Seekyo Therapeutics and VitroScan are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Seekyo Therapeutics, https://bouncewatch.com/company/seekyo, updated 7 June 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes